Programme
Monday, September 2
08.00 – 10:00
Registration
10:00-10:30
Opening
Jan Konvalinka (Director of IOCB Prague), Milan Pospíšil (Rector of UCT Prague), Eva Zažímalová (President of the Czech Academy of Sciences), Her Excellency Anna Azari (Ambassador of Israel to the Czech Republic)
10:30-11:10
Petra Ménová, UCT Prague, Czech Republic
How are new drugs born?
11:10-11:50
Deborah Fass, Weizmann Institute of Science, Rehovot, Israel
Structures of mucin glycoproteins inspire molecular methods for modulating mucosal functions
11:50-12:30
Milan Vrábel, IOCB Prague, Czech Republic
Chemical engineering of cell surfaces for cancer immunotherapy
12:30-13:50
Lunch
13:50-14:30
Marek Šťastný, Medical Department, Bristol-Myers Squibb, Czech Republic
Cancer immunotherapies based on anti-PD1: clinical perspectives and challenges
14:30-15:10
Stella Vukelic, AbbVie, Ludwigshafen, Germany
Molecular obesity – An addiction in drug discovery?
15:10-15:50
Jitka Riedl, Bicycle Therapeutics, Cambridge, UK
Attacking from all angles: EphA2 targeting Bicycle® peptides for precision guided cancer therapy via multiple approaches
15:50-16:20
Coffee break
16:20-17:00
David Margulies, Weizmann Institute of Science, Rehovot, Israel
Detecting proteins and protein-inhibitor interactions with ‘turn-on’ fluorescent molecular probes: design principles and applications in medical diagnosis, cell imaging and drug discovery
17:00-17:40
Andrea Brancale, UCT Prague, Czech Republic
Kick-start new drug design projects using computer-aided drug design
19:00
Welcome party
Tuesday, September 3
07:30 – 09:00
Registration
09:00-09:40
Peter H. Seeberger, Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany
Synthetic glycans as basis for vaccines, therapeutic antibodies and diagnostics
09:40-10:20
Christoph Rademacher, University of Vienna, Austria
Cell-specific targeted delivery of therapeutics
10:20-10:50
Coffee break
10:50-11:30
Frank Wagner, Charité, Berlin, Germany
Focus on early clinical trials
11:30-12:10
Oliviana Calin-Eller, E. Blum & Co. AG, Zurich, Switzerland
Patents: Why? What? How?
12:10-12:50
Valery Khrizanovsky, Weizmann Institute of Science, Rehovot, Israel
Senescent cells in aging and age-related disease: the good, the bad and the ugly
12:50-14:10
Lunch
14:10-15:40
Spin-offs: roundtable discussion
Panelists: Andrea Brancale, Oliviana Calin-Eller, Valery Khrizanovsky, Christoph Rademacher, Peter H. Seeberger, David Stíbal, Frank Wagner
Host: Aleš Vlk
15:50-17:30
Poster session + refreshments
Wednesday, September 4
07:30 – 09:00
Registration
09:00-09:40
Stephan Bachmann, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Catalysis as key technology for the synthesis and scale-up of APIs and their intermediates
09:40-10:20
Camille Correia, Merck Electronics KGaA, Darmstadt, Germany
Modular continuous automation for laboratories and production
10:20-10:50
Coffee break
10:50-11:30
Martina Benešová-Schäfer, German Cancer Research Center, Heidelberg, Germany
Pharmaceutical radiochemistry in modern nuclear medicine
11:30-12:10
Sima Lev, Weizmann Institute of Science, Rehovot, Israel
Triple-negative breast cancer: heterogeneity and targeted therapy
12:10-12:50
Kateřina Vávrová, Faculty of Pharmacy Hradec Kralove, Charles University, Czech Republic
Ceramides in the skin: extraordinary lipids for an extraordinary barrier
12:50-14:00
Lunch
14:00-18:00
Prague city tour
18:00
Social evening – Karolinum
Thursday, September 5
07:30 – 09:00
Registration
09:00-09:40
Jan Konvalinka, IOCB Prague, Czech Republic
Chemical-biology tools in drug development
09:40-10:20
Daniela Angst, Novartis, Basel, Switzerland
Remibrutinib, a covalent BTK inhibitor with best-in-class selectivity: discovery and clinical results
10:20-10:50
Coffee break
10:50-11:30
Roy Bar-Ziv, Weizmann Institute of Science, Rehovot, Israel
„Artificial Cells“ on a chip
11:30-12:10
Graciela Andrei, Rega Institute for Medical Research, KU Leuven, Belgium
Herpesvirus drug-resistance: challenges and opportunities
12:10-13:30
Lunch
13:30-14:10
Gideon Schreiber, Weizmann Institute of Science, Rehovot, Israel
Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration
14:10-14:50
Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel
Overcoming resistance of lung cancer to tyrosine kinase inhibitors
14:50-15:30
Richard Clarkson, Cardiff University, UK
Targeting cells responsible for metastatic disease
15:30-18:00
Excursions: UCT Brewery, IOCB labs
Friday, September 6
07:30 – 09:00
Registration
09:00-09:40
Pavlína Řezáčová, IOCB Prague, Czech Republic
Structure-assisted design of enzyme inhibitors
09:40-10:20
Igor Ulitsky, Weizmann Institute of Science, Rehovot, Israel
Therapeutic targeting of RNA molecules
10:20-10:50
Coffee break
10:50-11:30
Jitka Palich Fučíková, Sotio Biotech Department of Immunology, 2nd Medical school, Charles University, Czech Republic
The role of immune system in cancer therapy
11:30-12:10
Menachem Rubinstein, Weizmann Institute of Science, Rehovot, Israel
Directing viral vectors to specific cell types for oncolytic virotherapy and in vivo gene therapy
12:10-13:30
Lunch
13:30-14:10
Michal Tichý, IOCB Prague, Czech Republic
Kinase Inhibitors: From insoluble and promiscuous hit to drug candidate
14:10-14:50
Kvido Stříšovský, IOCB Prague, Czech Republic
The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling
14:50-15:00
Closing, best poster award
